A Polygenic Risk Score Assessment Reveals More Screening Participants with Clinically Significant Prostate Cancer Than Those Who Would Be Identified with PSA or MRI By Ogkologos - April 30, 2025 529 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BARCODE1 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Safety of Antibiotics in the Context of First-Line Chemo-Immunotherapy for Advanced... August 18, 2021 Air Is Life: The Navajo Nation’s Historic Commercial Tobacco Ban February 7, 2022 Cancer in My Community: Improving Access to Palliative Care in Indonesia January 13, 2022 FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2... August 29, 2025 Load more HOT NEWS Ability of Deep Learning to Accurately Diagnose Frequent STS Subtypes from... Durable Antitumour Activity of Pembrolizumab Plus Lenvatinib in Patients with Previously... Bowel Cancer Data Reinforce Need to Reduce Unnecessary Antibiotic Use [ESMO... How Do Black People with Cancer View Clinical Research?
